Cancers, Vol. 12, Pages 773: Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse –Bordeaux DATAML Registry Study
Cancers, Vol. 12, Pages 773: Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
Cancers doi: 10.3390/cancers12040773
Authors:
Sarah Bertoli
Pierre-Yves Dumas
Emilie Bérard
Laetitia Largeaud
Audrey Bidet
Eric Delabesse
Suzanne Tavitian
Noémie Gadaud
Thibaut Leguay
Harmony Leroy
Jean-Baptiste Rieu
Jean-Philippe Vial
François Vergez
Nicolas Lechevalier
Isabelle Luquet
Emilie Klein
Audrey Sarry
Anne-Charlotte De Grande
Christian Récher
Arnaud Pigneux
A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with standard of care. In this trial, the response rate with standard therapy was particularly low. We retrospectively assessed the characteristics and outcome of patients with R/R FLT3-mutated AML included in the Toulouse–Bordeaux DATAML registry. Among 347 patients who received FLT3 TKI-free intensive chemotherapy as first-line treatment, 174 patients were refractory (n = 48, 27.6%) or relapsed (n = 126, 72.4%). Salvage treatments consisted of intensive chemotherapy (n = 99, 56.9%), azacitidine or low-dose cytarabine (n = 9, 5.1%), other low-intensity treatments (n = 17, 9.8%), immediate allogeneic stem cell transp...
Source: Cancers - Category: Cancer & Oncology Authors: Sarah Bertoli Pierre-Yves Dumas Emilie B érard Laetitia Largeaud Audrey Bidet Eric Delabesse Suzanne Tavitian No émie Gadaud Thibaut Leguay Harmony Leroy Jean-Baptiste Rieu Jean-Philippe Vial Fran çois Vergez Nicolas Lechevalier Isabelle Luquet Emilie Tags: Article Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants